DNLIDenali Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of Denali Therapeutics Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNLIEsta | $3.2B#2 | — | 3.9x#3 | — | — | -21.2%#2 | — | -61.4%#4 | — | — | — | — |
| CGON | $6.5B#1 | — | 6.3x#4 | 1601.7x#2 | 254.7%#1 | -82.9%#3 | -4722.1%#2 | -15.6%#1 | -18.8%#1 | — | — | — |
| RVMDW | $2.8B#3 | — | 1.1x#1 | — | — | -88.5%#4 | — | -43.4%#2 | — | — | — | — |
| VIR | $1.8B#4 | — | 1.8x#2 | 26.0x#1 | -7.6%#2 | 16.1%#1 | -699.2%#1 | -44.6%#3 | — | — | 117.3%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice